Overview

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Status:
Enrolling by invitation
Trial end date:
2033-06-01
Target enrollment:
0
Participant gender:
All
Summary
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bellicum Pharmaceuticals
Criteria
Inclusion Criteria:

- Signed written informed consent by the patient or the patient's guardian for children
who are minors

- Enrolled on BP-004 protocol, received BPX-501 infusion, completed or discontinued from
the study, and are beyond Day +180.

Exclusion Criteria:

- Lack of parents'/guardian's informed consent for children who are minors

- Loss of allograft prior to 6 months